Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome

Clinical Immunology

Volumn 158, Issue 2, 2015, Pages 148-152

  Lai, Zhi wei ^a   Marchena Mendez, Ivan ^a   Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Anti phospholipid syndrome; Mechanistic target of rapamycin; MTOR; Oxidative stress; Systemic lupus erythematosus; Treg

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; SUPEROXIDE; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; CASE CONTROL STUDY; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; OXIDATIVE STRESS; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84928634094     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.024     Document Type: Article

References (32)

1. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011, 365:2110-2121.
2. Fernandez D., Bonilla E., Mirza N., Niland B., Perl A. Rapamycin reduces disease activity and normalizes T-cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2983-2988.
3. Fernandez D.R., Telarico T., Bonilla E., Li Q., Banerjee S., Middleton F.A., Phillips P.E., Crow M.K., Oess S., Muller-Esterl W., Perl A. Activation of mTOR controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 2009, 182:2063-2073.
4. Lai Z.-W., Borsuk R., Shadakshari A., Yu J., Dawood M., Garcia R., Francis L., Tily H., Bartos A., Faraone S.V., Phillips P.E., Perl A. mTOR activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J. Immunol. 2013, 191:2236-2246.
5. Lai Z.-W., Hanczko R., Bonilla E., Caza T.N., Clair B., Bartos A., Miklossy G., Jimah J., Doherty E., Tily H., Francis L., Garcia R., Dawood M., Yu J., Ramos I., Coman I., Faraone S.V., Phillips P.E., Perl A. N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arthritis Rheum. 2012, 64:2937-2946.
6. Sarbassov D.D., Sabatini D.M. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J. Biol. Chem. 2005, 280:39505-39509.
7. Yoshida S., Hong S., Suzuki T., Nada S., Mannan A.M., Wang J., Okada M., Guan K.L., Inoki K. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J. Biol. Chem. 2011, 286:32651-32660.
8. Perl A. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat. Rev. Rheumatol. 2013, 9:674-686.
9. Gergely P.J., Grossman C., Niland B., Puskas F., Neupane H., Allam F., Banki K., Phillips P.E., Perl A. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46:175-190.
10. Doherty E., Oaks Z., Perl A. Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antioxid. Redox Signal. 2014, 21:56-65.
11. Caza T.N., Fernandez D., Talaber G., Oaks Z., Haas M., Madaio M.P., Lai Z.-W., Miklossy G., Singh R.R., Chudakov D.M., Malorni W., Middleton F.A., Banki K., Perl A. HRES-1/RAB4-mediated depletion of DRP1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann. Rheum. Dis. 2014, 73:1887-1897.
12. + T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 1989, 143:103-112.
13. + DN T cells and contracts Tregs in SLE. J. Immunol. 2014, 192:4134-4144.
14. Koga T., Hedrich C.M., Mizui M., Yoshida N., Otomo K., Lieberman L.A., Rauen T., Crisp+n J.C., Tsokos G.C. CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. J. Clin. Invest. 2014, 124:2234-2245.
15. Fernandez D., Perl A. Metabolic control of T cell activation and death in SLE. Autoimmun. Rev. 2009, 8:184-189.
16. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 2012, 12:325-338.
17. Ray J.P., Craft J. PTENtiating autoimmunity through Treg cell deregulation. Nat. Immunol. 2015, 16:139-140.
18. + T cell metabolism reverses lupus. Sci. Transl. Med. 2015, 7:274ra18.
19. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25:1271-1277.
20. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725.
21. Petri M., Orbai A.M., Alarcon G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., Sturfelt G., Ramsey-Goldman R., Bae S.C., Hanly J.G., S+ínchez-Guerrero J., Clarke A., Aranow C., Manzi S., Urowitz M., Gladman D., Kalunian K., Costner M., Werth V.P., Zoma A., Bernatsky S., Ruiz-Irastorza G., Khamashta M.A., Jacobsen S., Buyon J.P., Maddison P., Dooley M.A., van Vollenhoven R.F., Ginzler E., Stoll T., Peschken C., Jorizzo J.L., Callen J.P., Lim S.S., Fessler B.J., Inanc M., Kamen D.L., Rahman A., Steinsson K., Franks A.G., Sigler L., Hameed S., Fang H., Pham N., Brey R., Weisman M.H., McGwin G., Magder L.S. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64:2677-2686.
22. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., DE Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). [see comment]. [136 refs]. J. Thromb. Haemost. 2006, 4:295-306.
23. Ioannou Y., Zhang J.Y., Qi M., Gao L., Qi J.C., Yu D.M., Lau H., Sturgess A.D., Vlachoyiannopoulos P.G., Moutsopoulos H.M., Rahman A., Pericleous C., Atsumi T., Koike T., Heritier S., Giannakopoulos B., Krilis S.A. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen b2-glycoprotein I. Arthritis Rheum. 2011, 63:2774-2782.
24. Giannakopoulos B., Krilis S.A. The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 2013, 368:1033-1044.
25. Perez-Sanchez C., Barbarroja N., Messineo S., Ruiz-Limon P., Rodriguez-Ariza A., Jimenez-Gomez Y., Khamashta M.A., Collantes-Estevez E., Cuadrado M.J., Aguirre M.A., Lopez-Pedrera C. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann. Rheum. Dis. 2014, (in press). 10.1136/annrheumdis-2013-204600.
26. Canaud G., Bienaimé F., Tabarin F., Bataillon G., Seilhean D., Noël L.-H., Dragon-Durey M.A., Snanoudj R., Friedlander G., Halbwachs-Mecarelli L., Legendre C., Terzi F. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 2014, 371:303-312.
27. Perl A., Hanczko R., Doherty E. Assessment of mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Meth. Mol. Med. Autoimmunity: Methods and Protocols 2012, 61-89. Springer, Clifton, NJ. A. Perl (Ed.).
28. high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007, 178:2579-2588.
29. Fujio K., Okamura T., Sumitomo S., Yamamoto K. Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity. Ann. Rheum. Dis. 2013, 72:ii85-ii89.
30. Perl A., Hanczko R., Lai Z.-W., Oaks Z., Kelly R., Borsuk R., Asara J.M., Phillips P.E. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics 2015, (in press). 10.1007/s11306-015-0772-0.
31. Warner L.M., Adams L.M., Sehgal S.N. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 1994, 37:289-297.
32. Desai B.N., Myers B.R., Schreiber S.L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:4319-4324.